Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Histalim

Histalim?uq=AFYHfsyn
2005 FOUNDED
M&A STATUS
31-40 EMPLOYEES
Buyout/LBO LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

Provider of histology, immunohistochemistry (IHC), In Situ Hybridization (ISH) and image analysis services. The company is engaged in development of new therapies in the domains of oncology and chronic diseases, including therapeutic antibody and new generation diagnostic tools. It also takes part in development projects for pharmaceutic products, medical devices and diagnostic tools.

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Private Equity-Backed
Primary Industry
Biotechnology
Other Industries
Drug Delivery
Parent Company
Primary Office
  • 126 Rue Emile Baudot
  • 34000 Montpellier
  • France

+33 04 00 00 00 00

Histalim Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Histalim‘s full profile, request access.

Request full access to PitchBook

Histalim Executive Team (1)

Name Title Board
Seat
Contact
Info
Jean-Philippe Coton Managing Director & Publication Manager